Genetically Hypoallergenic Dogs

Hello Summarians!

Someone used CRISPR to breed dogs that don't produce the protein responsible for most dog allergies, tested the results on a single person, and called it a proof of concept. That is technically accurate.

This week also covers epidural injections for neuropathic pain in dogs and cats that haven't responded to oral drugs. And a controlled trial of fecal transplants for chronic gut disease in dogs finds it didn't clearly beat placebo.

Three studies. One will generate more conversation than its data can support.

If VerSummary is valuable to you, please consider sending it on to a friend 😄 

Neuropathic Pain And Epidurals In Dogs

This retrospective case series evaluated the use of epidural injections to manage neuropathic pain in companion animals that had not responded to conventional medical therapy. Researchers reviewed medical records from 2015 to 2026 and identified six qualifying patients—four domestic shorthair cats and two dogs—with neuropathic pain caused by conditions including limb or tail amputation, blunt trauma, spinal surgery, intervertebral disc disease, neoplasia, and parturition. All animals had persistent clinical signs despite treatment with at least two oral analgesic medications.  

Clinical signs included self-mutilation, excessive licking, vocalization, allodynia, abnormal posture or gait, tail twitching, and behaviors that significantly reduced quality of life. Each patient received one or more epidural injections containing triamcinolone combined with either bupivacaine or ropivacaine, with some injections also including opioids, dexmedetomidine, or ketamine. Procedures were performed under sedation or light anesthesia using imaging guidance or established techniques to confirm correct needle placement. No complications related to the injections were reported.  

Treatment outcomes were encouraging. One cat experienced complete, lasting resolution of neuropathic pain after a single injection. The remaining cats showed substantial improvement, with pain relief lasting a median of six months, although repeat injections were sometimes required. Both dogs also experienced complete resolution of self-mutilation and meaningful improvement in neurological function, but the duration of benefit was shorter, ranging from two to six weeks. In several animals, repeat injections produced shorter periods of relief, likely reflecting progression of the underlying disease rather than reduced treatment effectiveness.  

The authors concluded that epidural analgesia may be a valuable option for dogs and cats with refractory neuropathic pain when oral medications fail. However, they emphasized that the study's small sample size, variable underlying diseases, lack of standardized treatment protocols, and reliance on owner-reported outcomes limit the strength of the conclusions. Larger, controlled clinical trials with validated neuropathic pain assessment tools are needed to determine the optimal drug combinations, treatment protocols, and long-term efficacy of epidural therapy in veterinary patients. 

Bergstein, O., Boesch, J. M., Thomson, A. C. S., & Todd-Donato, A. (2026). Epidural analgesia reduces or eliminates neuropathic pain refractory to oral medications in dogs and cats for weeks to months. American Journal of Veterinary Research https://doi.org/10.2460/ajvr.26.05.0237

Bottom line — May be useful if conventional therapy fails

Genetically Hypoallergenic Dog

This proof-of-concept study investigated whether CRISPR-Cas9 gene editing could eliminate the major dog allergen, Can f 1, thereby reducing allergic reactions in humans. Dog allergy affects approximately 15% of the population, and Can f 1, a protein produced primarily in saliva and skin glands, is responsible for most dog-specific IgE responses. Traditional approaches such as selecting “hypoallergenic” breeds, maintaining strict household hygiene, or using allergen immunotherapy have shown inconsistent success because they do not reduce allergen production at its biological source.  

Researchers used CRISPR-Cas9 genome editing to create a targeted mutation in the Can f 1 gene of canine fibroblast cells. These edited cells were used in somatic cell nuclear transfer to produce two cloned female beagle puppies. Genetic sequencing confirmed successful disruption of the Can f 1 gene, while extensive analyses found no detectable off-target genetic changes or large chromosomal abnormalities. The puppies developed normally, maintained healthy growth, exhibited normal behavior, and showed no apparent health problems during routine veterinary monitoring.  

Laboratory testing demonstrated that saliva, hair, and dander from the edited dogs contained no detectable Can f 1 protein, unlike samples from standard beagles, poodles, and goldendoodles. To determine whether this eliminated allergenicity, researchers performed skin prick testing in a single individual with documented Can f 1 sensitivity. While extracts from control dogs produced clear allergic skin reactions, extracts from the edited dogs produced no measurable response, suggesting that elimination of Can f 1 effectively prevented IgE-mediated allergic reactivity in this individual.  

The authors conclude that targeted removal of Can f 1 is compatible with normal canine development and may provide a fundamentally new strategy for reducing dog allergies by preventing allergen production rather than treating allergic symptoms. However, the study remains preliminary because it involved only two dogs and a single allergic participant. Larger studies involving additional breeds and people with diverse allergy profiles will be necessary before this approach can be considered a practical or broadly applicable solution. 

Walker MWG, Margolis C, Wiegand T, Gavin N, Loewy E. Targeted Genetic Knockout of Can f 1, the Major Allergen in Dogs. The CRISPR Journal. 2026;0(0). doi:10.1177/25731599261473124 

Bottom line — Hmmm…Interesting…Longterm effects???

FMT And Tylosin Responsive Dogs

This study evaluated whether oral fecal microbiota transplantation (FMT) could improve clinical outcomes and restore intestinal microbial balance in dogs with tylosin-responsive enteropathy (TRE), a form of chronic inflammatory enteropathy that responds to the antibiotic tylosin but commonly relapses after treatment is stopped. Because repeated antibiotic use raises concerns about antimicrobial resistance and long-term disruption of the gut microbiome, the researchers investigated whether FMT could provide a safer, microbiome-based alternative.  

In this prospective, randomized, double-blind, placebo-controlled clinical trial, 14 client-owned dogs were enrolled, although one placebo-treated dog was excluded because of pyometra, leaving seven dogs in the FMT group and six in the placebo group. Dogs received oral FMT capsules or placebo daily for four weeks. Investigators measured clinical disease activity, fecal consistency, intestinal permeability, and multiple fecal biomarkers, including the dysbiosis index, bacterial populations, bile acids, short-chain fatty acids, lactate, and calprotectin before and after treatment.  

Although relapse rates were numerically lower in the FMT-treated dogs than in placebo-treated dogs, these differences were not statistically significant. The dysbiosis index improved over time in both groups, suggesting some recovery of the intestinal microbiome regardless of treatment. FMT-treated dogs showed greater increases in Faecalibacterium species, bacteria associated with intestinal health, but many other microbial and metabolic markers—including bile acids, short-chain fatty acids, lactate, calprotectin, and intestinal permeability—did not differ significantly between treatment groups. Overall, microbiome restoration was incomplete, and only a small number of dogs achieved normalization of the dysbiosis index.  

The authors concluded that oral FMT was safe and capable of producing measurable but inconsistent changes in the intestinal microbiome. However, it did not demonstrate clear clinical superiority over placebo in this small study. They suggested that the limited response may reflect the study's small sample size, the severity of dysbiosis, or insufficient microbial dosing with oral capsules. Future studies should evaluate larger patient populations, longer treatment periods, and alternative protocols such as repeated rectal FMT or combined oral and rectal administration to determine whether microbiome-based therapies can provide a reliable long-term alternative to antibiotic treatment for dogs with chronic enteropathy. 

Hanifeh, M., Huhtinen, M., Ganz, H. H., Heilmann, R. M., Huang, W., Spillmann, T., & Suchodolski, J. S. (2026). Clinical trial reveals limited clinical and microbiome effects following oral fecal microbiota transplantation in dogs with chronic enteropathy responsive to tylosin. Journal of the American Veterinary Medical Association https://doi.org/10.2460/javma.26.03.0178

Bottom line — Disappointing.

Just putting things in perspective …